Wound care providers are currently facing growing challenges with payer coverage and reimbursement for skin substitutes used in chronic wound treatments. These products have come under close examination due to concerns over clinical efficacy, inconsistent evidence, and increased regulatory and fraud investigations. As a result, agencies like the Center for Medicare and Medicaid Services (CMS) and the Department of Justice (DOJ) are increasing oversight to ensure medical necessity, appropriate use, and ethical practices among manufacturers and providers.
What’s Driving the Increased Oversight?
Several key factors have prompted closer review of skin substitute use in wound care:
- Limited evidence
- Regulatory confusion
- High costs
- Faud investigations
Together, these issues have made it more difficult for providers to navigate payer policies and secure reimbursement.
Reasons for increased scrutiny include a lack of robust clinical evidence supporting outcomes, limited product evidence for certain wound types, improper marketing or misunderstood regulations regarding the use of human cells, tissue, or cellular or tissue-based products (HCT/Ps), and increased regulatory oversight to ensure these products are used appropriately. In addition, the high cost of skin substitutes is a major concern, and there are ongoing debates about whether the current evidence justifies the expenditure.
The Impact on Providers and Patients
Many payers have released coverage and reimbursement policies specific to the use of skin substitutes for diabetic foot ulcers and venous leg ulcers. However, providers often face uncertainty when using these products for other types of chronic wounds.
This ambiguity can lead to:
- Increased audit and claim denial risk
- Delays in reimbursement
- Potential loss of patient access to effective treatments
Without clear guidance, providers may face inconsistent payer decisions that disrupt care delivery and financial stability.
Evolving Guidance from CMS and Other Agencies
The good news is that agencies like CMS are working on clearer policies for coverage and reimbursement to ensure patients continue to have access to appropriate, high-quality wound care products.
In the meantime, providers should:
- Review each payer’s documentation and medical necessity requirements closely
- Maintain detailed clinical notes supporting each skin substitute application
- Ensure compliance with all regulatory and billing guidelines
Diligent documentation and proactive compliance are the best defense against denials and audits.
How We Can Help
Recent fraud investigations and reports from the Office of Inspector General (OIG) have led to increased oversight of skin substitute billing, making expert review critical for healthcare providers.
If you need help in navigating wound care skin substitute scrutiny, Dean Dorton can provide guidance on compliance, documentation, medical necessity, and cost-effective utilization.
